PTAB Denies Institution of IPR on Two Humira Patents


The PTAB has denied institution of inter partes review of two Abbvie patents that relate to HUMIRA (adalimumab).  On February 9, 2018, the PTAB denied Sandoz’s IPR2017-01824 on U.S. Patent No. 9,512,216, which is directed to a method of treating plaque psoriasis by subcutaneously administering a claimed regimen of adalimumab.   On the same day, the PTAB denied Sandoz’s IPR2017-10823 on U.S Patent No. 8,802,100 (the “’100 patent”), which is directed to stable aqueous pharmaceutical formulations comprising an anti-TNFα antibody.  The PTAB previously denied institution of three IPRs directed formulation patents related to the ‘100 patent, filed by Amgen and Coherus.

Big Molecule Watch will continue to bring you updates on IPRs related to biologics and to post important documents on our IPR tracker page.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:


Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.